CSIMarket
 


Nanostring Technologies Inc   (NSTG)
Other Ticker:  
 

Nanostring Technologies Inc 's Quick Ratio

NSTG's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 1.21 below Nanostring Technologies Inc average.

Within Biotechnology & Pharmaceuticals industry 109 other companies have achieved higher Quick Ratio than Nanostring Technologies Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1158 to 1163.

Explain Quick Ratio?
How much Cash & cash equivalents NSTG“s has?
What are NSTG“s Current Liabilities?


NSTG Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 52.21 % 20.42 % 16.95 % 12.86 % 14.52 %
Y / Y Cash & cash equivalent Change -19.62 % -8.81 % 23.95 % 5.68 % 9.24 %
Quick Ratio MRQ 1.21 1.84 2.1 1.92 2.3
NSTG's Total Ranking # 1163 # 1158 # 1176 # 1426 # 1329
Seq. Current Liabilities Change 24.18 % 7.66 % -1.48 % 15.55 % -1.75 %
Seq. Cash & cash equivalent Change -18.13 % -5.82 % 7.85 % -3.35 % -7.11 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 110
Healthcare Sector # 511
Overall Market # 1163


Quick Ratio Statistics
High Average Low
11.79 3.06 0.7
(Mar 31 2021)   (Dec 31 2019)




Financial Statements
Nanostring Technologies Inc 's Current Liabilities $ 78 Millions Visit NSTG's Balance sheet
Nanostring Technologies Inc 's Cash & cash equivalent $ 94 Millions Visit NSTG's Balance sheet
Source of NSTG's Sales Visit NSTG's Sales by Geography


Cumulative Nanostring Technologies Inc 's Quick Ratio

NSTG's Quick Ratio for the trailling 12 Months

NSTG Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 52.21 % 20.42 % 16.95 % 12.86 % 14.52 %
Y / Y Cash & cash equivalent TTM Growth -19.62 % -8.81 % 23.95 % 5.68 % 9.24 %
Quick Ratio TTM 1.73 2.03 2.18 2.15 2.19
Total Ranking TTM # 1223 # 1039 # 3526 # 1227 # 365
Seq. Current Liabilities TTM Growth 24.18 % 7.66 % -1.48 % 15.55 % -1.75 %
Seq. Cash & cash equivalent TTM Growth -18.13 % -5.82 % 7.85 % -3.35 % -7.11 %


On the trailing twelve months basis Due to growth in Current Liabilities in the III Quarter 2023 to $77.53 millions, cumulative Quick Ratio decreased to 1.73 below the Nanostring Technologies Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 128 other companies have achieved higher Quick Ratio than Nanostring Technologies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 1039 to 1223.

Explain Quick Ratio?
How much Cash & cash equivalents NSTG“s has?
What are NSTG“s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 129
Healthcare Sector # 645
Within the Market # 1223


trailing twelve months Quick Ratio Statistics
High Average Low
6.53 3.01 1.73
(Mar 31 2021)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Omega Therapeutics Inc   3.33 $ 89.300  Millions$ 26.816  Millions
Miromatrix Medical inc   3.23 $ 16.062  Millions$ 4.966  Millions
Fennec Pharmaceuticals inc   3.19 $ 12.399  Millions$ 3.892  Millions
Aligos Therapeutics Inc   3.13 $ 70.429  Millions$ 22.468  Millions
Poseida Therapeutics Inc   3.10 $ 238.837  Millions$ 76.973  Millions
Gamida Cell Ltd   3.06 $ 63.154  Millions$ 20.654  Millions
Relay Therapeutics Inc   2.98 $ 151.328  Millions$ 50.748  Millions
Vericel Corporation  2.93 $ 105.343  Millions$ 35.946  Millions
Exelixis Inc   2.93 $ 1,103.387  Millions$ 376.816  Millions
Inmune Bio Inc   2.91 $ 41.813  Millions$ 14.356  Millions
Armata Pharmaceuticals Inc   2.84 $ 23.958  Millions$ 8.441  Millions
Lineage Cell Therapeutics Inc   2.60 $ 41.332  Millions$ 15.881  Millions
Orchard Therapeutics Plc  2.54 $ 125.413  Millions$ 49.375  Millions
Arcellx Inc   2.54 $ 439.716  Millions$ 173.149  Millions
Precision Biosciences Inc  2.41 $ 122.231  Millions$ 50.617  Millions
Halozyme Therapeutics Inc   2.38 $ 274.227  Millions$ 115.185  Millions
Regenxbio Inc   2.37 $ 301.887  Millions$ 127.346  Millions
Windtree Therapeutics Inc  2.25 $ 7.365  Millions$ 3.270  Millions
Adaptimmune Therapeutics Plc  2.15 $ 161.728  Millions$ 75.146  Millions
Immunitybio inc   2.10 $ 189.796  Millions$ 90.324  Millions
Amgen Inc   2.05 $ 34,741.000  Millions$ 16,954.000  Millions
Genfit S a   2.02 $ 87.124  Millions$ 43.098  Millions
C4 Therapeutics Inc   2.01 $ 60.971  Millions$ 30.271  Millions
Adma Biologics Inc   1.82 $ 74.157  Millions$ 40.715  Millions
Innate Pharma Sa  1.78 $ 79.078  Millions$ 44.393  Millions
Vaxart Inc   1.76 $ 19.799  Millions$ 11.268  Millions
Biomx Inc   1.76 $ 22.450  Millions$ 12.784  Millions
Repligen Corp  1.75 $ 630.779  Millions$ 360.049  Millions
Moderna Inc   1.73 $ 7,573.000  Millions$ 4,385.000  Millions
Eiger Biopharmaceuticals Inc   1.69 $ 27.501  Millions$ 16.319  Millions

Date modified: 2023-11-07T12:35:48+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com